Krasney Karen 4

What Happened

• Karen Krasney, EVP and General Counsel of Capricor Therapeutics (CAPR), reported exercising 2,500 stock options on 2025-12-30 at an exercise price of $1.39 per share, costing $3,475 in aggregate.
• The same report shows a disposition of 2,500 derivative shares at $0.00 on the same date. The two entries result in no net increase in reported share count from these line items.

Key Details

• Transaction date: 2025-12-30; Exercise price: $1.39; Acquisition value: $3,475.
• Disposition: 2,500 derivative shares at $0.00 (listed as a derivative disposition).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — Option was originally granted Jan 3, 2017 (covered 25,000 shares at $2.55), adjusted for a 1-for-10 reverse split on June 4, 2019 and repriced to $1.39 on Feb 12, 2020. F2 — Shares vested 1/48th monthly beginning Feb 1, 2017.
• Filing timeliness: Form 4 was filed on 2026-03-27 for a 2025-12-30 transaction (filed roughly three months after the trade), which appears delinquent under the usual two-business-day reporting rule.

Context

• This was an option exercise (transaction code M). The simultaneous derivative disposition at $0.00 is commonly used to indicate share surrender or company withholding to cover taxes or exercise-related obligations, though the filing does not explicitly state the reason.
• Exercises and related withholding/surrenders are typically administrative and do not necessarily signal a change in insider sentiment; purchases (out-of-pocket acquisitions) tend to be more informative for bullish signals.